Home

The treatment of one of the most common urological diseases, a chronic aseptic prostatitis, is an exigeant problem. Used methods of pharmacotherapy are insufficiently effective and after treatment, as a rule, there comes a recrudescence. The new prostatotropic agent Prostamax is related to bioregulator peptides at experimental chronic aseptic inflammation of prostate gland. It is established that Prostamax reduces intensity of signs of a chronic inflammation, prevents development of sclerotic and atrophic processes and intensifies sexual activity of animals. Efficiency of the preparation Prostamax surpasses that among widespread prostatotropic agents derived from

Bremelanotide, also known as PT-141, is a peptide that binds to the body's MC3R and MC4R melanocortin receptors and is comparable to the alpha MSH and melanocortin. When it binds, it activates the hypothalamus and other brain areas, increasing sexual desire. Although it was once believed to be utilized to treat both male and female sexual problems, studies have shown that it is also effective in premenopausal women. Therefore, PT-141 is also employed in women who naturally have sexual abnormalities such as female sexual arousal disorder and hypoactive sexual desire. 
- The benefits of PT 141 Bremelanotide include:
- Higher sex drive and increased sexual desire
- Greater sexual frequency
- Treatment for erectile dysfunction and/or impotence
- Effective treatment for premenopausal women with Hypoactive Sexual Disorder
- Sexual Dysfunction in women (Sexual Arousal Disorder)
- Increased levels of natural energy.

PTD-DBM is a safe and effective treatment to regrow a full head of hair in both men and women. It shows the following benefits:


- Prevents pattern baldness - the most common type of hair loss in both men and women
- Stimulates new hair follicles
- Accelerated hair regrowth
- New follicle development in areas of baldness
- Treats androgenetic alopecia 

FRESHLY PREPARED SOLUTION

Epitalon - 100mg + Thymalin - 100mg.

Retatrutide is a peptide characterized as a triple GGG agonist, targeting three key incretin receptors: GLP-1R (Glucagon-Like Peptide-1 Receptor), GIPR (Gastric Inhibitory Peptide Receptor), and GCGR (Glucagon Receptor). This multifaceted approach allows retatrutide to exert a comprehensive influence on metabolic processes, including enhancing satiety signals, slowing gastric emptying, and increasing the breakdown of stored fats and glycogen.

Research indicates that Retinalamin can be used for:
- Diabetic retinopathy
- Myopic Disease
- Retinitis pigmentosa
- Age-related macular degeneration
- Other eye diseases
- Primary open-angle glaucoma
- Chorioretinitis
 
Total Spray: 82 (2,44 mg per spray)


FRESHLY PREPARED SOLUTION

Research indicates that Retinalamin can be used for:
- Diabetic retinopathy
- Myopic Disease
- Retinitis pigmentosa
- Age-related macular degeneration
- Other eye diseases
- Primary open-angle glaucoma
- Chorioretinitis

RTD-1 is an antibacterial peptide. It has activity against gram-positive bacteria, gram-negative bacteria, Antiviral and fungi.

Antioxidant, Anti-aging, Cataracts, Glaucoma, Alcoholism, Asthma, Cancer, Diseases of the heart and blood vessels, Liver disease, Chronic Fatigue Syndrome, Thyroiditis, Boosting the immune system, Memory loss, Alzheimer’s disease, Osteoarthritis, Autoimmune diseases, Parkinson’s disease, Detoxifying metals and drugs, Cystic fibrosis, For preventing toxicity of chemotherapy.

Semaglutide is a modified form of the naturally present GLP-1 peptide, which is recognized for its ability to regulate blood sugar and boost insulin release. Studies indicate that Semaglutide could also have positive effects on cardiac, hepatic, and pulmonary health, as well as potentially mitigating the impact of Alzheimer's disease. Additionally, it has been found to effectively curb hunger by slowing down the emptying of the stomach and limiting the movement of the intestines. As a GLP-1 analog, it is designed to both enhance insulin production and inhibit the release of glucagon in a manner dependent on glucose levels. Semaglutide has demonstrated the largest weight loss of any obesity medication to date with reductions of approximately 15% of initial weight at 68 weeks.